CL2023000800A1 - Compuestos de cromanol para el tratamiento de la insuficiencia cardíaca - Google Patents
Compuestos de cromanol para el tratamiento de la insuficiencia cardíacaInfo
- Publication number
- CL2023000800A1 CL2023000800A1 CL2023000800A CL2023000800A CL2023000800A1 CL 2023000800 A1 CL2023000800 A1 CL 2023000800A1 CL 2023000800 A CL2023000800 A CL 2023000800A CL 2023000800 A CL2023000800 A CL 2023000800A CL 2023000800 A1 CL2023000800 A1 CL 2023000800A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- heart failure
- chromanol
- compounds
- tetramethylchroman
- Prior art date
Links
- SEBPXHSZHLFWRL-UHFFFAOYSA-N 3,4-dihydro-2,2,5,7,8-pentamethyl-2h-1-benzopyran-6-ol Chemical class O1C(C)(C)CCC2=C1C(C)=C(C)C(O)=C2C SEBPXHSZHLFWRL-UHFFFAOYSA-N 0.000 title abstract 3
- 206010019280 Heart failures Diseases 0.000 title 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 abstract 2
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 abstract 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 abstract 2
- -1 4-(2-hydroxyethyl)piperazin-1-yl Chemical group 0.000 abstract 1
- 125000000687 hydroquinonyl group Chemical class C1(O)=C(C=C(O)C=C1)* 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención se relaciona con ciertos compuestos de cromanol, quinona o hidroquinona y derivados de estos para el tratamiento de la insuficiencia cardíaca con fracción de eyección reducida (HFrEF). Específicamente, la presente invención se relaciona con compuestos de cromanol elegidos de S-(6-hidroxi-2,5,7,8-tetrametilcroman-2il)(piperazin-1-il)metanona y S-(6-hidroxi-2,5,7,8-tetrametilcroman-2-il)(4-(2-hidroxietil)piperazin-1-il)metanona, y sales farmacéuticamente aceptables de estos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2026511A NL2026511B1 (en) | 2020-09-21 | 2020-09-21 | Compounds for treatment of heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000800A1 true CL2023000800A1 (es) | 2023-10-30 |
Family
ID=73643308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000800A CL2023000800A1 (es) | 2020-09-21 | 2023-03-20 | Compuestos de cromanol para el tratamiento de la insuficiencia cardíaca |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230330060A1 (es) |
| EP (1) | EP4213825A1 (es) |
| JP (1) | JP2023543721A (es) |
| CN (1) | CN116322661A (es) |
| AU (1) | AU2021346236A1 (es) |
| CA (1) | CA3195766A1 (es) |
| CL (1) | CL2023000800A1 (es) |
| NL (1) | NL2026511B1 (es) |
| WO (1) | WO2022058620A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2031091B1 (en) * | 2022-02-28 | 2023-09-07 | Sulfateq Bv | Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008531558A (ja) * | 2005-02-25 | 2008-08-14 | イーライ リリー アンド カンパニー | 新規なリポオキシゲナーゼ阻害剤 |
| RU2422136C1 (ru) | 2010-03-03 | 2011-06-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт кардиологии Сибирского отделения РАМН | Способ комплексного иммуномодулирующего лечения пациентов с хронической сердечной недостаточностью со сниженной фракцией выброса левого желудочка |
| US10894787B2 (en) * | 2010-09-22 | 2021-01-19 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| LT2872497T (lt) | 2012-07-12 | 2017-04-25 | Khondrion Ip B.V. | Chromanilo dariniai, skirti mitochondrinių ligų gydymui |
| NL2010010C2 (en) * | 2012-12-19 | 2014-06-23 | Sulfateq B V | Compounds for protection of cells. |
| EP3359521A1 (en) * | 2015-10-08 | 2018-08-15 | Khondrion Ip B.V. | Novel compounds for treating mitochondrial disease |
| KR102660473B1 (ko) * | 2017-04-05 | 2024-04-24 | 콘드리온 아이피 비.브이. | 미토콘드리아 질환의 신규 치료 |
| EP3672593A1 (en) * | 2017-08-25 | 2020-07-01 | Sulfateq B.V. | Medicaments for the treatment of vasoconstriction related diseases or disorders |
| WO2020096862A1 (en) | 2018-11-08 | 2020-05-14 | Edwards Lifesciences Corporation | Percutaneous treatment of heart failure with reduced ejection fraction |
-
2020
- 2020-09-21 NL NL2026511A patent/NL2026511B1/en active
-
2021
- 2021-09-21 EP EP21777556.8A patent/EP4213825A1/en active Pending
- 2021-09-21 JP JP2023518173A patent/JP2023543721A/ja active Pending
- 2021-09-21 CA CA3195766A patent/CA3195766A1/en active Pending
- 2021-09-21 US US18/026,834 patent/US20230330060A1/en active Pending
- 2021-09-21 AU AU2021346236A patent/AU2021346236A1/en active Pending
- 2021-09-21 CN CN202180064500.XA patent/CN116322661A/zh active Pending
- 2021-09-21 WO PCT/EP2021/075967 patent/WO2022058620A1/en active Application Filing
-
2023
- 2023-03-20 CL CL2023000800A patent/CL2023000800A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3195766A1 (en) | 2022-03-24 |
| US20230330060A1 (en) | 2023-10-19 |
| AU2021346236A9 (en) | 2024-02-08 |
| NL2026511B1 (en) | 2022-05-24 |
| JP2023543721A (ja) | 2023-10-18 |
| EP4213825A1 (en) | 2023-07-26 |
| AU2021346236A1 (en) | 2023-05-04 |
| WO2022058620A1 (en) | 2022-03-24 |
| CN116322661A (zh) | 2023-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003041A1 (es) | Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica | |
| CL2020002511A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| PE20200009A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| CL2018001145A1 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| EA201101668A1 (ru) | Редокс-активные терапевтические средства для лечения митохондриальных нарушений | |
| UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
| CL2022001520A1 (es) | Compuestos para el tratamiento de la enfermedad de alzheimer | |
| BR112016024057A2 (pt) | inibidores de quinases heterocíclicos | |
| CL2023000800A1 (es) | Compuestos de cromanol para el tratamiento de la insuficiencia cardíaca | |
| HRP20050533A2 (en) | Aminoindazole derivatives and use thereof as kinase inhibitors | |
| BR112012002134B8 (pt) | compostos inibidores de apaf-1 | |
| CU20170026A7 (es) | Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf | |
| CU20210035A7 (es) | Compuestos de azalactam como inhibidores de hpk 1 | |
| CL2023001461A1 (es) | Inhibidores de prmt5 novedosos | |
| MX2021002111A (es) | Sales de adición de ácido de succinato y fumarato de derivados de piperazina útiles como inhibidores de glucosidasa. | |
| DOP2022000211A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| UY38912A (es) | Inhibidores del factor d del complemento para administración oral | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| CO2023005342A2 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer | |
| CL2023001339A1 (es) | Un inhibidor de magl. | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| CO2022006087A2 (es) | Métodos para el tratamiento de la trombocitopenia inmunitaria mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo | |
| AR059617A1 (es) | Derivados de aminopirimidina, medicamentos que los contienen, y usos para el tratamiento de enfermedades en las que la regulacion, inhibicion y/o la modulacion de la hsp90 desempena un papel importante. | |
| ECSP23088732A (es) | Moduladores de trex1 | |
| DOP2023000195A (es) | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática |